Additionally, Recursion plans to present updated clinical data from the TUPELO trial during a webinar scheduled for December 8, 2025. This presentation will provide further insights into the safety ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In this week’s edition of InnovationRx, we look at the biotech deal frenzy, Recursion’s incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here. Merck ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Among the myriad abilities that humans possess, which ones are uniquely human? Language has been a top candidate at least since Aristotle, who wrote that humanity was “the animal that has language.” ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. 10 stocks we like better than ...